Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 81INDUSTRY 43NIH 6NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 6Head & Neck 2Genitourinary 2Gastrointestinal 2Breast 2Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Hodgkin Disease 1

Interventions

Cyclophosphamide 90Vincristine 83Doxorubicin 69Prednisone 66Cytarabine 59Methotrexate 58Rituximab 49Etoposide 43Radiotherapy 41Dexamethasone 41Filgrastim 39Leucovorin 27Mercaptopurine 26Granulocyte Colony-Stimulating Factor 26pegaspargase 22Calcium Dobesilate 22Daunorubicin 21Asparaginase 20merphos 19Specimen Handling 18Thioguanine 17Hydrocortisone 16Bleomycin 16Peripheral Blood Stem Cell Transplantation 14Vinblastine 13Gene Expression Profiling 13Methylprednisolone 12Ifosfamide 12Gemcitabine 12dexamethasone acetate 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × pembrolizumab × Lymphoid × Clear all
NCT05180097 2026-02-02

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Canadian Cancer Trials Group

Phase 2 Recruiting
84 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡